Open an account

AstraZeneca

AZNCF · LONDON

$168.82+$4.87 (+2.97%)TodayMarket closed ·
Prev close $163.95

About AZNCF

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.

Employees
96,100
Headquarters
CAMBRIDGE, Cambridgeshire
Listed
Sep 21, 2007
Sector
Health Care
Industry
Pharmaceuticals
Website
astrazeneca.com

AZNCF key statistics

Market cap
192.31B
Price-earnings ratio
24.56
Dividend yield
1.91%
Average volume
1.53M
Volume
1.69M
Open price
$166.77
High today
$169.24
Low today
$166.66
52 Week high
$15,730.00
52 Week low
$11,404.00

AstraZeneca (AZNCF) at a glance

As of Oct 20, 2026, AstraZeneca (AZNCF) shares are priced at $168.82, giving the company a market cap of 192.31B, a price-to-earnings ratio of 24.56 and a dividend yield of 1.91%.

Today the stock has traded between $166.66 and $169.24. The current price is 1.3% above the day's low and 0.2% below its high.

Volume so far is 1.69M shares, in line with the average of 1.53M shares a day.

Over the past year AstraZeneca has ranged from $11,404.00 to $15,730.00, and now sits -260% of the way up that range.

AstraZeneca met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported $2.63 per share against an estimate of $2.55.

AZNCF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 3.6% on average.

  1. Q3 FY24: reported $2.08 per share against an estimate of $2.07
  2. Q4 FY24: reported $2.09 per share against an estimate of $2.10
  3. Q1 FY25: reported $2.49 per share against an estimate of $2.28
  4. Q2 FY25: reported $2.17 per share against an estimate of $2.21
  5. Q3 FY25: reported $2.38 per share against an estimate of $2.35
  6. Q4 FY25: reported $2.12 per share against an estimate of $2.15
  7. Q1 FY26: reported $2.58 per share against an estimate of $2.59
  8. Q2 FY26: reported $2.63 per share against an estimate of $2.55

AZNCF news

  • Press releasePRNewswire

    Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.